Document is current

Article History

Received: 20 March 2025

Accepted: 2 September 2025

First Online: 30 September 2025

Declarations

:

: The trial protocol was approved by the ethics committee of the General Hospital of Northern Theater Command (NO. k-2018-3). The study complied with the principles of the Declaration of Helsinki. Written informed consent was obtained from all participants or their legally authorized representatives before randomization.

: Not applicable.

: GWS has received speaker honoraria from Medtronic, Amgen, Boehringer Ingelheim; has served as a consultant to Robocath, Daiichi Sankyo, Vectorious, Miracor, Apollo Therapeutics, Cardiac Success, Occlutech, Millennia Biopharma, Remote Cardiac Enablement, Ablative Solutions, Abbott, Oxitope, Valfix, Zoll, HeartFlow, Shockwave, Impulse Dynamics, Adona Medical, HighLife, Elixir, Elucid Bio, Aria, Alleviant, FBR Medical, Myochron, Colibri; and has equity/options from Cardiac Success, Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Valfix, Xenter. Dr. Stone’s employer, Mount Sinai Hospital, receives research grants from Shockwave, Biosense-Webster, Bioventrix, Abbott, Abiomed, Cardiovascular Systems Inc, Phillips, Vascular Dynamics, Pulnovo, V-wave and PCORI (via Weill Cornell Medical Center). No other conflicts of interest were declared.